Literature DB >> 25655287

Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases.

Bojan Stanimirov1, Karmen Stankov, Momir Mikov.   

Abstract

BACKGROUND: The well-known functions of bile acids (BAs) are the emulsification and absorption of lipophilic xenobiotics. However, the emerging evidences in the past decade showed that BAs act as signaling molecules that not only autoregulate their own metabolism and enterohepatic recirculation, but also as important regulators of integrative metabolism by activating nuclear and membrane-bound G protein-coupled receptors. The present review was to get insight into the role of maintenance of BA homeostasis and BA signaling pathways in development and management of hepatobiliary and intestinal diseases. DATA SOURCES: Detailed and comprehensive search of PubMed and Scopus databases was carried out for original and review articles.
RESULTS: Disturbances in BA homeostasis contribute to the development of several hepatobiliary and intestinal disorders, such as non-alcoholic fatty liver disease, liver cirrhosis, cholesterol gallstone disease, intestinal diseases and both hepatocellular and colorectal carcinoma.
CONCLUSION: Further efforts made in order to advance the understanding of sophisticated BA signaling network may be promising in developing novel therapeutic strategies related not only to hepatobiliary and gastrointestinal but also systemic diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25655287     DOI: 10.1016/s1499-3872(14)60307-6

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  16 in total

Review 1.  An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.

Authors:  Frank J Gonzalez; Changtao Jiang; Andrew D Patterson
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

Review 2.  Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.

Authors:  Momir Mikov; Maja Đanić; Nebojša Pavlović; Bojan Stanimirov; Svetlana Goločorbin-Kon; Karmen Stankov; Hani Al-Salami
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

Review 3.  The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease.

Authors:  Yiming Ni; Mengna Lu; Yuan Xu; Qixue Wang; Xinyi Gu; Ying Li; Tongxi Zhuang; Chenyi Xia; Ting Zhang; Xiao-Jun Gou; Mingmei Zhou
Journal:  Front Microbiol       Date:  2022-06-27       Impact factor: 6.064

Review 4.  Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.

Authors:  Wei Jia; Guoxiang Xie; Weiping Jia
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-10-11       Impact factor: 46.802

5.  Controlled bile acid exposure to oesophageal mucosa causes up-regulation of nuclear γ-H2AX possibly via iNOS induction.

Authors:  Bo Jiang; Shengqian Zhao; Zhen Tao; Jin Wen; Yancheng Yang; Yin Zheng; Hongling Yan; Ying Sheng; Aimin Gao
Journal:  Biosci Rep       Date:  2016-07-07       Impact factor: 3.840

Review 6.  Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles.

Authors:  Nebojša Pavlović; Svetlana Goločorbin-Kon; Maja Ðanić; Bojan Stanimirov; Hani Al-Salami; Karmen Stankov; Momir Mikov
Journal:  Front Pharmacol       Date:  2018-11-08       Impact factor: 5.810

Review 7.  Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?

Authors:  Hiroshi Fukui
Journal:  Diseases       Date:  2019-11-12

Review 8.  Bile Salt Hydrolases: At the Crossroads of Microbiota and Human Health.

Authors:  Mélanie Bourgin; Aicha Kriaa; Héla Mkaouar; Vincent Mariaule; Amin Jablaoui; Emmanuelle Maguin; Moez Rhimi
Journal:  Microorganisms       Date:  2021-05-22

Review 9.  Gut Microbiota and Host Reaction in Liver Diseases.

Authors:  Hiroshi Fukui
Journal:  Microorganisms       Date:  2015-10-28

10.  Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis.

Authors:  Junhui Yu; Shan Li; Jing Guo; Zhengshui Xu; Jianbao Zheng; Xuejun Sun
Journal:  Cell Death Dis       Date:  2020-08-17       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.